Featured Stories

Canadian Study Finds Actos Raises Bladder Cancer Risk by 22 Percent

Yet another study is confirming the association between the diabetes drug, Actos, and bladder cancer. This latest research, published today in the Canadian Medical Association Journal, found that taking Actos raised the risk of bladder cancer among diabetics by about one-fifth.

Read More

Fracking Should be Kept 600m From Aquifers, Study Says

New research on the safety of hydraulic fracturing (fracking) suggests new wells should not be dug within 600 meters of a water aquifer because underground fractures can extend about that far from a dug well. According to a report from UK’s The Guardian newspaper, researchers and geologists at Durham University have ...

Read More

Conspiracy Claims in Talcum Powder Case Survive Motion to Dismiss

Conspiracy Claims in Talcum Powder Case Survive Motion to Dismiss

E. District of Missouri denied motion to dismiss conspiracy claims. Lawsuit alleges the defendants conspired to misrepresent true dangers with use of talcum powder.

Read More

Fracking Boom Changing Way of Life in Pennsylvania's Northern Tier

In just a few years, the impact of hydraulic fracturing (fracking) drilling on northeastern Pennsylvania is hard to miss. Thousands of natural gas wells have been opened in that area specifically in the last five years as companies look to exploit the vast Marcellus shale formation about two miles below the ...

Read More

New York Property Owners Challenge Binghamton Fracking Ban

According to a Reuters report, the landowners believe the Binghamton, N.Y., city council and Mayor acted against proper protocol when voting to ban fracking drilling the the city. Instead, they feel the city should have consulted with the Broome County Planning Commission before approving the ban.

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

Transvaginal Mesh Lawsuit Trial

$5.5 Million Awarded to Plaintiffs in First Transvaginal Mesh Lawsuit Trial

An award of $5.5 million has been made in the first trial over a transvaginal mesh lawsuit. The jury found against medical device maker, C.R. Bard, and its Avaulta Plus transvaginal mesh. The jury agreed that Bard’s Avaulta Plus transvaginal mesh caused numerous and painful injuries in a California woman. ...

Read More

Decision on Pradaxa Bleeding Lawsuit Multidistrict Litigation Expected Soon

Victims of alleged Pradaxa injuries are awaiting word on whether their lawsuits will be consolidated in a multidistrict litigation. According to a report from The Madison Record, so far just over two dozen Pradaxa bleeding lawsuits have been filed in federal courts throughout the U.S.

Read More

Medtronic Settles Charges Over Kickbacks To Doctors

Medical device giant, Medtronic Inc., is settling charges over kickbacks to doctors. The firms just agreed to pay $23.5 million to settle claims it paid physicians kickbacks in exchange for their use of its pacemakers and defibrillators, according to a U.S. Justice Department announcement yesterday. The company was accused of seeking ...

Read More

Levaquin Complaint can be Amended to Include FDA Warning, Court Says

In May 2016, the U.S. Food and Drug Administration (FDA) warned about the risks of fluoroquinolone antibiotics, which include Levaquin, Avelox and Cipro. The agency said that, given the risk of potentially permanent side effects, these medications should only be used in situations where no other treatment options are available for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections.

Fluoroquinolones are the subject of a multidistrict litigation (MDL) underway in Minnesota. A court recently ruled that plaintiffs can amend the Master Complaint to include this most recent FDA announcement. At least 484 lawsuits have been filed over Levaquin, Cipro and Avelox in the District of Minnesota. An additional 40 lawsuits have been filed in state courts. Continue reading

Posted in Legal News |

Zithromax Linked to Rare but Extremely Serious Skin Side Effect

Zithromax, a widely prescribed antibiotic, has been linked to a number of severe side effects, including the serious allergic skin reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Stevens-Johnson is “a rare, serious disorder” of the skin and mucous membranes. SJS is usually a reaction to a medication or an infection. SJS frequently begins with flu-like symptoms, followed by a painful red or purplish rash that spreads and blisters. Continue reading

Posted in Health Concerns, Pharmaceuticals, Zithromax |

FDA Updates Abilify Label to Include Compulsive Behaviors

The U.S. Food and Drug Administration (FDA) has updated the warning label on Abilify, Abilify Maintena, Aristada and generic aripiprazole to include information about compulsive behavior. According to the safety announcement, there have been reports of uncontrollable urges to gamble, binge eat, shop and have sex in patients taking these drugs. According to the FDA announcement, the compulsive behaviors generally stopped when the dosage was lowered or drug discontinued.

The current label included pathological gambling as a reported side effect, but the FDA stated that this was not an accurate description of impulse-control problems identified. Additionally, the label did not include information about compulsive behaviors other than gambling. As a result, the agency is updating the warning label. Continue reading

Posted in Legal News |

FDA Revises Warning Label on Fluoroquinolone Antibiotics

The U.S. Food and Drug Administration (FDA) has approved labeling changes on fluoroquinolone antibiotics, which include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive). In a news release issued Tuesday, the agency said the Boxed Warning and the Warning and Precautions section of the label would be revised to warn of “disabling and potentially permanent side effects” affecting tendons, muscles, joints, nerves and the central nervous system.

Fluoroquinolones fight bacterial infections by preventing growth or killing bacteria. In November 2015, an FDA Advisory Committee reviewed new safety information involving two or more side effects that occur simultaneously, and the potential to lead to permanent damage. The committee concluded that the risks of fluoroquinolones generally outweighed the benefits in patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections. In May, the FDA released a drug safety communication stating that use of fluoroquinolones should be limited to situations where no alternative treatments are available.
The new safety label will reflect current information showing that both oral and injectable fluoroquinolones were associated with “disabling side effects” that can affect the tendons, muscles, joints, nerves and the central nervous system, the FDA said. The agency’s news release stated that the side effects may be permanent, and occur anywhere from hours to weeks after treatment. Continue reading

Posted in Legal News |

Zofran Birth Defect Lawsuit Update: “Sequence Discovery” Issue

Plaintiffs in more than 200 birth defect lawsuits have raised concerns over the pharmaceutical company GlaxoSmithKline’s (GSK) new proposal for Sequenced Discovery. Parents say the company neglected to warn patients and health experts of its anti-nausea drug Zofran’s alleged potential to cause serious birth defects, according to The Legal Examiner.

On June 3, 2016, GSK suggests possible order, or “sequence” in the document’s language, for how discovery should proceed. In the discovery phase, both parties are allowed to demand evidence from one another. For its part, GSK wants this litigation to turn to two major questions: Continue reading

Posted in Birth Defects, Health Concerns, Pharmaceuticals |

Dilantin Linked to Stevens-Johnson Syndrome, a Dangerous Skin Condition

Dilantin, the anti-epileptic drug that has been in use for decades is one of many drugs associated with the related skin conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Though these conditions are rare, when they do occur they put the patient at risk for permanent skin and organ damage and blindness. SJS/TEN can be fatal, Top Class Actions reports. Continue reading

Posted in Dilantin, Health Concerns, Lamictal, Pharmaceuticals, Zithromax |

Levaquin Plaintiffs Allowed to Include Updated FDA Safety Warnings in Legal Complaints

Hundreds of product liability lawsuits involving the fluoroquinolone antibiotics Levaquin, Cipro and Avelox are moving toward trial in a multidistrict litigation (MDL) in the U.S. District Court, District of Minnesota.

In June 2016, the court granted a motion from the plaintiffs to amend the master complaint to include information about the U.S. Food & Drug Administration’s (FDA) May 2016 safety announcement for fluoroquinolone antibiotics. The court said that doing so would not greatly expand the scope of the proceedings. Continue reading

Posted in Cipro, Legal News, Levaquin, Pharmaceuticals |

Xarelto Lawsuits Have Added Credibility Based on Scholarly Studies

The makers of Xarelto, an anticoagulant that was credited as a breakthrough in blood clot prevention, is battling numerous lawsuits. An alleged connection between an elevated risk for serious hemorrhages and Xarelto are now being lent possible increased credibility through recent studies, reports the Digital Journal.

The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. It is manufactured by Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The initial purpose of the medication was to prevent blood clots in patients with pulmonary embolisms, deep vein thrombosis, and those recovering from knee and hip replacement surgeries. A short while after it was approved, Xarelto’s uses were expanded to treat atrial fibrillation, a heart condition that increases the risk of stroke. Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals |

DePuy Orthopaedics Denied a Delay for September Pinnacle Hip Implant Trial

Texas federal Judge Ed Kinkeade has refused to delay the scheduled September trial in the ongoing multidistrict litigation involving DePuy Orthopaedics Pinnacle metal-on-metal (MoM) hip implants.

DePuy Orthopaedics requested the delay after a March trial resulted in a $502 million award to five plaintiffs who alleged serious injuries from DePuy Pinnacle hip devices. DePuy wanted the September trial delayed until the appeal of the March verdict had been decided but Judge Kinkeade ruled that the September trial would go forward. Continue reading

Posted in Defective Medical Devices, Depuy, Metal Hip Implants |

October 2017 Trial Expected in British Metal-on-Metal Hip Litigation

In one of Britain’s largest product liability group actions in recent years, lawyers for more than 600 individuals injured by early failure of metal-on-metal hip implants were in court recently for a hearing.

The lawyers for the plaintiffs in a number of metal-on-metal group actions met with legal representatives for major hip manufacturers including Smith & Nephew, Zimmer, Corin Cormet and DePuy Synthes (a subsidiary of Johnson & Johnson). Continue reading

Posted in Defective Medical Devices, Health Concerns, Metal Hip Implants |

© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.